Cargando…
Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease
In the past decade, G protein-coupled receptors have emerged as drug targets, and their physiological and pathological effects have been extensively studied. Among these receptors, GPR119 is expressed in multiple organs, including the liver. It can be activated by a variety of endogenous and exogeno...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265056/ https://www.ncbi.nlm.nih.gov/pubmed/34233623 http://dx.doi.org/10.1186/s11658-021-00276-7 |